Abstract
The enzyme reverse transcriptase (RT) is essential in the replication of human immunodeficiency virus (HIV). Non-nucleoside reverse transcriptase inhibitors or NNRTIs are a promising class of anti-HIV drugs, which block the chemical step of DNA polymerization reaction by binding at the allosteric site of RT, leading to a viral suppression. A major limitation to the success of therapy with NNRTIs is the rapid development of drug-resistant mutants. In this work we have used molecular modeling, virtual screening, flexible docking, molecular interaction field, pharmacophoric alignment, toxicology predictions, and molecular dynamics simulations in order to design new molecules with potential higher selectivity and enzymatic inhibitory activity over K103N RT enzyme, which is the most common mutation to emerge.
Current Bioactive Compounds
Title: Virtual Screening and Toxicology Prediction of Novel Potential Non- Nucleoside Reverse Transcriptase Inhibitors
Volume: 5 Issue: 2
Author(s): Adriana Mieco Namba, Vinicius Barreto da Silva, Thais Mitleton Borges Ramos, Roberta Bonassa Vermelho, Natalia Zanon Baptista and Carlos Henrique Tomich de Paula da Silva
Affiliation:
Abstract: The enzyme reverse transcriptase (RT) is essential in the replication of human immunodeficiency virus (HIV). Non-nucleoside reverse transcriptase inhibitors or NNRTIs are a promising class of anti-HIV drugs, which block the chemical step of DNA polymerization reaction by binding at the allosteric site of RT, leading to a viral suppression. A major limitation to the success of therapy with NNRTIs is the rapid development of drug-resistant mutants. In this work we have used molecular modeling, virtual screening, flexible docking, molecular interaction field, pharmacophoric alignment, toxicology predictions, and molecular dynamics simulations in order to design new molecules with potential higher selectivity and enzymatic inhibitory activity over K103N RT enzyme, which is the most common mutation to emerge.
Export Options
About this article
Cite this article as:
Namba Mieco Adriana, da Silva Barreto Vinicius, Borges Ramos Mitleton Thais, Vermelho Bonassa Roberta, Baptista Zanon Natalia and de Paula da Silva Tomich Carlos Henrique, Virtual Screening and Toxicology Prediction of Novel Potential Non- Nucleoside Reverse Transcriptase Inhibitors, Current Bioactive Compounds 2009; 5 (2) . https://dx.doi.org/10.2174/157340709788452028
DOI https://dx.doi.org/10.2174/157340709788452028 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulatory T Cells: Major Players in the Tumor Microenvironment
Current Pharmaceutical Design Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015
Current Medicinal Chemistry Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Lentiviral Vectors for Gene Therapy of HIV-1 Infection
Current Gene Therapy Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review
Current Drug Therapy Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga
Current Pharmacogenomics and Personalized Medicine The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer
Reviews on Recent Clinical Trials Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics Toward the Development of Inhibitors Directed against Mammalian DDAH Proteins: Considerations from Homology Modeling of DDAH-2 and DDAH Activity Tracing in Tissue Homogenate
Letters in Drug Design & Discovery Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy